Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 275

1.

Physicians' Knowledge About FDA Approval Standards and Perceptions of the "Breakthrough Therapy" Designation.

Kesselheim AS, Woloshin S, Eddings W, Franklin JM, Ross KM, Schwartz LM.

JAMA. 2016 Apr 12;315(14):1516-8. doi: 10.1001/jama.2015.16984. No abstract available.

PMID:
27115269
2.

Patients' Knowledge, Beliefs, and Distress associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey.

Freiman MR, Clark JA, Slatore CG, Gould MK, Woloshin S, Schwartz LM, Wiener RS.

J Thorac Oncol. 2016 Mar 1. pii: S1556-0864(16)00355-5. doi: 10.1016/j.jtho.2016.01.018. [Epub ahead of print]

PMID:
26961390
3.

US Food and Drug Administration Approval of Flibanserin: Even the Score Does Not Add Up.

Woloshin S, Schwartz LM.

JAMA Intern Med. 2016 Apr 1;176(4):439-42. doi: 10.1001/jamainternmed.2016.0073. No abstract available.

PMID:
26926770
4.

Prefrontal glutamate correlates of methamphetamine sensitization and preference.

Lominac KD, Quadir SG, Barrett HM, McKenna CL, Schwartz LM, Ruiz PN, Wroten MG, Campbell RR, Miller BW, Holloway JJ, Travis KO, Rajasekar G, Maliniak D, Thompson AB, Urman LE, Kippin TE, Phillips TJ, Szumlinski KK.

Eur J Neurosci. 2016 Mar;43(5):689-702. doi: 10.1111/ejn.13159. Epub 2016 Feb 22.

PMID:
26742098
5.

Do plant traits predict the competitive abilities of closely related species?

Schwartz LM, Gibson DJ, Young BG.

AoB Plants. 2015 Dec 31;8. pii: plv147. doi: 10.1093/aobpla/plv147.

6.

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.

Shao R, Taylor SL, Oh DS, Schwartz LM.

Oncotarget. 2015 Dec 1;6(38):40507-18. doi: 10.18632/oncotarget.5943. Review.

7.

A Randomized Trial Testing US Food and Drug Administration "Breakthrough" Language.

Krishnamurti T, Woloshin S, Schwartz LM, Fischhoff B.

JAMA Intern Med. 2015 Nov;175(11):1856-8. doi: 10.1001/jamainternmed.2015.5355. No abstract available.

PMID:
26390245
8.

Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.

Drug Saf. 2015 Sep;38(9):845. doi: 10.1007/s40264-015-0329-1. No abstract available.

PMID:
26201399
9.

Three-state analytic theory of two-dimensional nuclear magnetic resonance in systems with coupled macro- and micropores.

Johnson DL, Schwartz LM.

Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Jun;91(6):062406. Epub 2015 Jun 29.

PMID:
26172724
10.

The dengue vaccine pipeline: Implications for the future of dengue control.

Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr.

Vaccine. 2015 Jun 26;33(29):3293-8. doi: 10.1016/j.vaccine.2015.05.010. Epub 2015 May 16. Review.

11.

Methodological approaches to evaluate the impact of FDA drug safety communications.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J.

Drug Saf. 2015 Jun;38(6):565-75. doi: 10.1007/s40264-015-0291-y. Erratum in: Drug Saf. 2015 Sep;38(9):845.

PMID:
25968811
12.

The immune signaling pathways of Manduca sexta.

Cao X, He Y, Hu Y, Wang Y, Chen YR, Bryant B, Clem RJ, Schwartz LM, Blissard G, Jiang H.

Insect Biochem Mol Biol. 2015 Jul;62:64-74. doi: 10.1016/j.ibmb.2015.03.006. Epub 2015 Apr 7.

PMID:
25858029
13.

Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project.

McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, Petrick JL, Alavanja MC, Andreotti G, Boggs DA, Buring JE, Chan AT, Freedman ND, Gapstur SM, Hollenbeck AR, Hou L, King LY, Koshiol J, Linet M, Palmer JR, Poynter JN, Purdue M, Robien K, Schairer C, Sesso HD, Sigurdson A, Wactawski-Wende J, Zeleniuch-Jacquotte A.

Br J Cancer. 2015 Mar 31;112(7):1266-72. doi: 10.1038/bjc.2015.58.

14.

Attitudes about low-dose computed tomography screening for lung cancer: a survey of American Thoracic Society Clinicians.

Simmons J, Gould MK, Woloshin S, Schwartz LM, Wiener RS.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):483-6. doi: 10.1164/rccm.201409-1747LE. No abstract available.

15.

Experimental identification of diffusive coupling using 2D NMR.

Song YQ, Carneiro G, Schwartz LM, Johnson DL.

Phys Rev Lett. 2014 Dec 5;113(23):235503. Epub 2014 Dec 4.

PMID:
25526135
16.

US Food and Drug Administration and design of drug approval studies.

Woloshin S, Schwartz LM, Frankel B, Faerber A.

JAMA. 2014 Nov 26;312(20):2163-5. doi: 10.1001/jama.2014.13329. No abstract available.

PMID:
25423223
17.

Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.

Howlader N, Mariotto AB, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):255-64. doi: 10.1093/jncimonographs/lgu022.

18.

When do changes in cancer survival mean progress? The insight from population incidence and mortality.

Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97. doi: 10.1093/jncimonographs/lgu014.

19.

Cancer survival: an overview of measures, uses, and interpretation.

Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S, Schwartz LM.

J Natl Cancer Inst Monogr. 2014 Nov;2014(49):145-86. doi: 10.1093/jncimonographs/lgu024. Erratum in: J Natl Cancer Inst Monogr. 2015 May;2015(51):97.

20.

Analytic theory of two-dimensional NMR in systems with coupled macro- and micropores.

Johnson DL, Schwartz LM.

Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Sep;90(3):032407. Epub 2014 Sep 29.

PMID:
25314457
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk